Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
Active, not recruiting · NCT04647916 · Registry updated 2026-05-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases | Neoplasms by Site, brain disorder, central nervous system cancer, central nervous system disorder, invasive breast carcinoma, metastatic malignant neoplasm in the brain, neoplasm, nervous system disorder | Active, not recruiting | Phase 2 | 2026-05-06 | NCT04647916 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Gilead Sciences | 180 |
| National Cancer Institute (NCI) | 3015 |
| SWOG Cancer Research Network | 67 |
296 results · Page 1 of 12
Research sites
Swipe the table sideways for more columns.